CD274 and esophageal cancer: Several trials are ongoing at this moment with immune checkpoint inhibitors, both anti-PD1 and anti-PD-L1 antibodies, investigating patients with gastric, GE junction or esophageal cancer not only in advanced/metastatic disease setting, but also in adjuvant, neoadjuvant, or perioperative indications.